Autolus extends the biotech IPO hot streak, adding $150M and bringing 2-day tally to $718M
Promising new cell therapy tech can still excite investors.
Autolus extended this week’s hot biotech IPO streak, pricing an upsized package of 8.8 million shares at $17 — the high end of the range — raising $150 million for their next stage of work. Insiders had lined up for about $60 million of the shares that had been on offer.
The UK-based Autolus was spun out of the lab of Martin Pule at University College London with some binding technology that they say can give them a safer approach to targeting CD19, along with BCMA and TACI programs in the works where they plan to leap past the current pioneers in blood cancers while expanding their reach into solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
